Back

Prospective validation of a predictive model and simplified score for the diagnosis of transthyretin cardiac amyloidosis: the PROVALTA study

10 May 2026 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: Evolving management of cardiomyopathies: early detection, precision diagnostics, and emerging treatments Autoimmune/Chronic Inflammatory Disorders and Heart Disease Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Cristina Goena Vives

Donostia University Hospital, Donostia (Spain)

5 More presentations in this session

Presentation thumbnail
Design and rationale of DemonsTTRate: a global, long-term observational study to evaluate vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
Doctor P. Garcia-Pavia (Majadahonda, ES)
Abstract Slides
Presentation thumbnail
Impact of the implementation of standardised early identification and diagnosis of transthyretin amyloidosis in high-risk patients: protocol of a high-quality diagnostic study (HI-QUAL ATTR)
Doctor H. Shi (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Consistency of T-Amylo diagnostic performance across patient subgroups: the PROVALTA study
Doctor C. Goena Vives (Donostia, ES)
Abstract Slides
Presentation thumbnail
Psychosocial determinants of quality of life in patients with hypertrophic cardiomyopathy
Doctor M. Lisiak (Wroclaw, PL)
Abstract Slides
Presentation thumbnail
Wild type transthyretin amyloidosis: real-life experience of tafamidis use and frailty analysis of treated patients
Mrs M. Faraudo (Sant Joan Despi (Barcelona), ES)
Abstract Slides

Access the full session

Session thumbnail
Evolving management of cardiomyopathies: early detection, precision diagnostics, and emerging treatments

The Event

Event poster

Heart Failure 2026

10 May 2026 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources